Optimal dosing and dynamic distribution of vaccines in an influenza pandemic

American Journal of Epidemiology

Volumn 169, Issue 12, 2009, Pages 1517-1524

  Wood, James ^a   McCaw, James ^b   Becker, Niels ^c   Nolan, Terry ^b   MacIntyre, C Raina ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c The Australian National University   (Australia)

Author keywords

Disease outbreaks; Influenza, human; Mass immunization; Models, theoretical

Indexed keywords

INFLUENZA VACCINE;

ANTIGEN; DISEASE CONTROL; DISEASE TRANSMISSION; DOSE-RESPONSE RELATIONSHIP; DRUG DEVELOPMENT; DRUG USER; EPIDEMIOLOGY; INFLUENZA; PUBLIC HEALTH; THEORETICAL STUDY; VACCINATION; VACCINE;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; OPTIMAL DRUG DOSE; PANDEMIC; PREVALENCE; SEROCONVERSION; COMPARATIVE STUDY; EPIDEMIC; IMMUNIZATION; STATISTICAL MODEL; STATISTICS; THEORETICAL MODEL; TIME; UNITED STATES;

DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, STATISTICAL; MODELS, THEORETICAL; TIME FACTORS; UNITED STATES;

EID: 67649148485     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp072     Document Type: Article

References (27)

1. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis. 2003;36(12):1552-1561.
2. Fedson D. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy. 2005;26(1):4-29.
3. Daems R, Del Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine. 2005;23(50): 5732-5742.
4. Caley P, Becker NG, Philp DJ. The waiting time for intercountry spread of pandemic influenza [electronic article]. PLoS ONE. 2007;2(1):e143.
5. Colizza V, Barrat A, Barthelemy M, et al. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions [electronic article]. PLoS Med. 2007;4(1):e13.
6. Cooper BS, Pitman RJ, Edmunds WJ, et al. Delaying the international spread of pandemic influenza [electronic article]. PLoS Med. 2006;3(6):e212.
7. Commonwealth of Australia. The Australian Health Management Plan for Pandemic Influenza. 2008. (http://www.flupandemic.gov.au/internet/panflu/ publishing.nsf/Content/ahmppi). (Accessed February 27, 2009).
8. US Department of Health and Human Services. HHS Pandemic Influenza Plan. 2005. (http://www.hhs.gov/pandemicflu/plan/pdf/ HHSPandemicInfluenzaPlan.pdf). (Accessed February 27, 2009).
9. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006;367(9523):1657-1664.
10. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343-1351.
11. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370(9587): 580-589.
12. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006;368 (9540):991-997.
13. Leroux-Roels I, Bernhard R, Gérard P, et al. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine [electronic article]. PLoS ONE. 2008;3(2):e1665.
14. Riley S, Wu J, Leung GM. Optimizing the dose of prepandemic influenza vaccines to reduce the infection attack rate [electronic article]. PLoS Med. 2007;4(6):e218.
15. Hobson D, Curry R, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972;70(4):767-777.
16. Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis. 2006;194(2):159-167.
17. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol. 2005;161(4):303-306.
18. Germann TC, Kadau K, Longini IM Jr, et al. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A. 2006;103(15):5935-5940.
19. Mylius SD, Hagenaars TJ, Lugnér AK, et al. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine. 2008;26(29-30):3742-3749.
20. Dushoff J, Plotkin J, Viboud C, et al. Vaccinating to protect a vulnerable subpopulation [electronic article]. PLoS Med. 2007;4(5):e174.
21. Halloran ME, Hayden FG, Yang Y, et al. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol. 2007;165(2): 212-221.
22. Bootsma MC, Ferguson NM. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci U S A. 2007;104(18):7588-7593.
23. Caley P, Philp DJ, McCracken K. Quantifying social distancing arising from pandemic influenza. J R Soc Interface. 2008; 5(23):631-639.
24. Vynnycky E, Edmunds WJ. Analyses of the 1957 (Asian) influenza pandemic in the United Kingdom and the impact of school closures. Epidemiol Infect. 2008;136(2):166-179.
25. Ferguson NM, Cummings DA, Cauchemez S, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature. 2005;437(7056):209-214.
26. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775-785.
27. Halloran ME, Ferguson NM, Eubank S, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc Natl Acad Sci U S A. 2008;105(12): 4639-4644.